lung adenocarcinoma
Conditions
Interventions
Healthy control group:no
Placebo control group:Shuanghuang Shengbai granule placebo 15g/ bag (twice a day, 2 bags each time),for 21 days
Treatment group:Shuanghuang Shengbai granule 15g/ bag (twice a day, 2 bags each time),for 21 days
Sponsors
Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 85 Years
Inclusion criteria
Inclusion criteria: 1. patients with pathologically or cytologically confirmed stage III lung adenocarcinoma and first postoperative chemotherapy; 2. meet the criteria for clinical evidence identification in Chinese medicine; 3. patients aged 18 - 85 years old; 4. Patients have undergone NP (vincristine + cisplatin) chemotherapy regimen, protocol description: vincristine (NVB) 25mg/m2 intravenous d1, d8 + cisplatin (DDP) 75mg/m2/d intravenous d1, (21 days for 1 cycle); 5. Patients developed grade I - II myelosuppression after standard NP chemotherapy regimen; the degree of myelosuppression was classified as grade 0 to IV according to WHO: grade 0: leukocytes = 4.0×10^9/L, hemoglobin = 110 g/L, platelets = 100×109/L, grade I: leukocytes (3.0-3.9)×10^9/L, hemoglobin 95-100 g/L, platelets (75 to 99) × 109/L, grade II: leukocytes (2.0 to 2.9) × 10^9/L, hemoglobin 80 to 94 g/L, platelets (50 to 74) × 10^9/L, grade III: leukocytes (1.0 to 1.9) × 10^9/L, hemoglobin 65 to 79 g/L, platelets (25 to 49) × 10^9/L, grade IV: leukocytes (0 to 1.0) × 10^9/L, hemoglobin <65 g/L, platelets <25 × 10^9/L. 6. Patients who have signed the informed consent form.
Exclusion criteria
Exclusion criteria: 1. patients with pathologically or cytologically confirmed stage III lung adenocarcinoma and first postoperative chemotherapy. 2. meet the criteria for clinical evidence identification in Chinese medicine 3. patients aged 18 - 85 years old. 4. Patients have undergone NP (vincristine + cisplatin) chemotherapy regimen, protocol description: vincristine (NVB) 25mg/m2 intravenous d1, d8 + cisplatin (DDP) 75mg/m2/d intravenous d1, (21 days for 1 cycle). 5. Patients developed grade I - II myelosuppression after standard NP chemotherapy regimen; the degree of myelosuppression was classified as grade 0 to IV according to WHO: grade 0: leukocytes = 4.0×109/L, hemoglobin = 110 g/L, platelets = 100×109/L, grade I: leukocytes (3.0-3.9)×109/L, hemoglobin 95-100 g/L, platelets ( 75 to 99) × 109/L, grade II: leukocytes (2.0 to 2.9) × 109/L, hemoglobin 80 to 94 g/L, platelets (50 to 74) × 109/L, grade III: leukocytes (1.0 to 1.9) × 109/L, hemoglobin 65 to 79 g/L, platelets (25 to 49) × 109/L, grade IV: leukocytes (0 to 1.0) × 109/L, hemoglobin <65 g/L, platelets <25 × 109/L. 6. Patients who have signed the informed consent form.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| it is formulated according to the evaluation standard of TCM clinical syndrome score of lung cancer in the clinical guiding principles of new traditional Chinese medicine.;Metabonomics test; | — |
Secondary
| Measure | Time frame |
|---|---|
| Routine blood test;liver function;Renal function;electrocardiogram test;Fecal routine test;urinalysis; | — |
Countries
China
Contacts
Public ContactWenlian Chen
Longhua Hospital Affiliated to Shanghai University of traditional Chinese Medicine
Outcome results
None listed